Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial

2015 ◽  
Vol 16 (15) ◽  
pp. 1556-1568 ◽  
Author(s):  
Edith A Perez ◽  
Ahmad Awada ◽  
Joyce O'Shaughnessy ◽  
Hope S Rugo ◽  
Chris Twelves ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Open Label ◽  
Phase 3 ◽  
Multicentre Phase ◽  
Previously Treated ◽  
Etirinotecan Pegol ◽  
Versus Treatment

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

2014 ◽  
Vol 15 (7) ◽  
pp. 689-699 ◽  
Author(s):  
Ian E Krop ◽  
Sung-Bae Kim ◽  
Antonio González-Martín ◽  
Patricia M LoRusso ◽  
Jean-Marc Ferrero ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Trastuzumab Emtansine ◽  
Her2 Positive ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase ◽  
Versus Treatment

scholarly journals Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial

SpringerPlus ◽  
2016 ◽  
Vol 5 (1) ◽  
Author(s):  
Javier Cortés ◽  
Hope S. Rugo ◽  
Chris Twelves ◽  
Ahmad Awada ◽  
Edith A. Perez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Phase 3 ◽  
Etirinotecan Pegol

scholarly journals EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer

2019 ◽  
Vol 15 (28) ◽  
pp. 3209-3218 ◽  
Author(s):  
Aditya Bardia ◽  
Philippe Aftimos ◽  
Teeru Bihani ◽  
Alfred T Anderson-Villaluz ◽  
JungAh Jung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Advanced Breast Cancer ◽  
Endocrine Resistance ◽  
Progression Free Survival ◽  
Advanced Breast ◽  
Phase Iii ◽  
Open Label ◽  
Er Positive ◽  
Previously Treated

Elacestrant is a novel, nonsteroidal, orally bioavailable selective estrogen receptor degrader (SERD) that has demonstrated activity in patients with estrogen receptor (ER)-positive/HER2-negative breast cancer previously treated with endocrine therapies including fulvestrant and/or CDK 4/6 inhibitor therapy, and in those with ESR1 mutations ( ESR1-mut) known to confer endocrine resistance. Herein, we describe the design and methodology of EMERALD, an international, multicenter, randomized, open-label, active-controlled, Phase III clinical study comparing the efficacy and safety of elacestrant to standard-of-care endocrine monotherapy treatment (fulvestrant or an aromatase inhibitor, per investigator’s choice) in patients with ER-positive/HER2-negative advanced breast cancer. Primary end points are progression-free survival in ESR1-mut patients and in all patients (NCT03778931; EudraCT 2018-002990-24).

Sign in / Sign up

Export Citation Format

Share Document